Arcturus' self-amplifying COVID-19 mRNA vaccine meets Phase 3 primary efficacy endpoint
Arcturus Therapeutics Holdings Inc. has reported topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, its self-amplifying mRNA COVID-19 vaccine candidate.
View the full story here: https://www.biopharma-reporter.com/Article/2022/04/20/Arcturus-s-self-amplifying-COVID-19-mRNA-vaccine-meets-Phase-3-primary-efficacy-endpoint